These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 18607587

  • 1. Lysostaphin: an antistaphylococcal agent.
    Kumar JK.
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
    [Abstract] [Full Text] [Related]

  • 2. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP, Gemmell CG, Coote PJ.
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [Abstract] [Full Text] [Related]

  • 3. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
    LaPlante KL.
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
    [Abstract] [Full Text] [Related]

  • 5. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW, Patron RL, Goldstein BP, Archer GL.
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1355-60. PubMed ID: 9624475
    [Abstract] [Full Text] [Related]

  • 6. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC, Foster-Frey J, Donovan DM.
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [Abstract] [Full Text] [Related]

  • 7. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2009 Jul; 64(1):94-100. PubMed ID: 19398455
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
    Graham S, Coote PJ.
    J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
    [Abstract] [Full Text] [Related]

  • 10. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.
    Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2002 Dec; 43(12):3712-6. PubMed ID: 12454041
    [Abstract] [Full Text] [Related]

  • 11. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM, Kokai-Kun JF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
    [Abstract] [Full Text] [Related]

  • 12. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization.
    Shah A, Mond J, Walsh S.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2704-7. PubMed ID: 15215130
    [Abstract] [Full Text] [Related]

  • 13. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland.
    Bramley AJ, Foster R.
    Res Vet Sci; 1990 Jul; 49(1):120-1. PubMed ID: 2382049
    [Abstract] [Full Text] [Related]

  • 14. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
    Howden BP, Grayson ML.
    Clin Infect Dis; 2006 Feb 01; 42(3):394-400. PubMed ID: 16392088
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus.
    Sugai M, Fujiwara T, Ohta K, Komatsuzawa H, Ohara M, Suginaka H.
    J Bacteriol; 1997 Jul 01; 179(13):4311-8. PubMed ID: 9209049
    [Abstract] [Full Text] [Related]

  • 17. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin.
    Francius G, Domenech O, Mingeot-Leclercq MP, Dufrêne YF.
    J Bacteriol; 2008 Dec 01; 190(24):7904-9. PubMed ID: 18835985
    [Abstract] [Full Text] [Related]

  • 18. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.
    Climo MW, Ehlert K, Archer GL.
    Antimicrob Agents Chemother; 2001 May 01; 45(5):1431-7. PubMed ID: 11302806
    [Abstract] [Full Text] [Related]

  • 19. [Topical use of lysostaphin for Staphylococcus aureus infection of burn wounds in mice].
    Huan JN.
    Zhonghua Wai Ke Za Zhi; 1992 May 01; 30(5):270-1, 316. PubMed ID: 1289000
    [Abstract] [Full Text] [Related]

  • 20. Hydrogel delivery of lysostaphin eliminates orthopedic implant infection by Staphylococcus aureus and supports fracture healing.
    Johnson CT, Wroe JA, Agarwal R, Martin KE, Guldberg RE, Donlan RM, Westblade LF, García AJ.
    Proc Natl Acad Sci U S A; 2018 May 29; 115(22):E4960-E4969. PubMed ID: 29760099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.